---
title: "Tvardi Therapeutics (TVRD.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TVRD.US/norm.md"
symbol: "TVRD.US"
name: "Tvardi Therapeutics"
parent: "https://longbridge.com/en/quote/TVRD.US.md"
datetime: "2026-03-05T12:32:04.962Z"
locales:
  - [en](https://longbridge.com/en/quote/TVRD.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TVRD.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TVRD.US/norm.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/TVRD.US/norm.md) | [繁體中文](https://longbridge.com/zh-HK/quote/TVRD.US/norm.md)


# Tvardi Therapeutics (TVRD.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.5900 | -1.00 | -1.50 | -1.99 | -2.14 |
| ROE | -72.73% | -49.24% | 39.96% | - | - |
| Revenue | - | - | - | - | - |
| Net income | -5.53M | 4.17M | -9.58M | -12.71M | -5.51M |
| Operating income | -5.94M | -8.87M | -4.35M | -10.80M | -5.68M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| A&L | 39.02M | 43.75M | 27.81M | 35.20M | 12.51M |
| Leverage | 1.40 | 1.33 | -1.84 | -6.25 | 1.79 |
| BVPS | 2.97 | 3.51 | -15.72 | -14.24 | -12.27 |
| Turnover | - | - | - | - | - |
| Cash & STI | 36.46M | 40.99M | 22.31M | 31.61M | 9.44M |
| Inv & Rec | - | - | - | - | - |
| LT assets | 223000.00 | 249000.00 | 275000.00 | 300000.00 | 310000.00 |
| Net debt | -36.23M | -40.74M | 13.73M | -1.05M | -9.14M |

## Cash Flow Statement (USD)

| Indicator | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -4.26M | -5.87M | -7.69M | -4.83M | -6.66M |
| Investing CF | 5.35M | -9.55M | -10.88M | - | - |
| Financing CF | -322000.00 | 24.63M | -1.60M | 27.01M | -14000.00 |
| Free CF | -2.84M | -2.20M | -7.07M | - | - |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | 28.30M | - |
| CapEx | - | - | - | - | - |